The FDA’s safety probe of CAR-T therapies has resulted in a call to add a class-wide boxed warning to these medicines, alerting patients and prescribers of their potential risk of secondary T-cell malignancies.
All six commercial CAR-T therapies will be affected, including J&J’s Legend Biotech-partnered Carvykti (ciltacabtagene autoleucel), Novartis’ Kymriah (tisagenlecleucel), BMS’s Abecma (idecabtagene vicleucel) and Breyanzi (lisocabtagene maraleucel) and Gilead’s Yescarta (axicabtagene ciloleucel) and Tecartus (brexucabtagene autoleucel).
The FDA on Friday sent out six letters to their respective manufacturers notifying them that the drug class has been associated with the risk of developing secondary cancers “with serious outcomes, including hospitalization and death.”
“FDA identified postmarketing adverse event and clinical trial reports describing occurrence of mature T cell malignancies, including CAR-positive tumors, following treatment with BCMA- and CD19-directed genetically modified autologous T cell immunotherapies,” the regulator said in the letters, while stopping short of establishing a causal connection between treatment and the secondary cancers.
The companies now have 30 days to either submit their proposed changes to their products’ safety labels or file a rebuttal statement if they disagree with the FDA’s assessment.
The FDA first announced that it was looking into the safety of CAR-T therapies in November 2023, after it had flagged instances of T-cell malignancies in patients who had been treated with these products. One such case, according to the regulator, was a CAR-positive lymphoma.
At the time, the FDA said that the benefits of CAR-T therapies still outweigh their potential risk but also noted that patients and participants receiving the treatment through clinical trials “should be monitored life-long for new malignancies.”
However, in response to the FDA’s safety investigation, oncologists have come out in defense of CAR-T therapies asserting that secondary blood malignancies are rare and that their risk is not enough to outweigh the treatment’s benefit for patients whose cancers have already progressed after chemotherapy and radiation.
“I doubt you will meet a CAR-T treating physician who will change their practice due to this warning,” Rahul Banerjee, a physician-researcher specializing in multiple myeloma at the Fred Hutchinson Cancer Center in Seattle, told BioSpace in a December 2023 interview.
Meanwhile, the FDA’s probe has triggered similar reviews by health regulatory authorities around the world, including the U.K.’s Medicines and Healthcare products Regulatory Agency, the E.U.’s European Medicines Agency and South Korea’s Ministry of Food and Drug Safety.
Check out our AAV CDMO service to expedite your gene therapy research
PackGene is a CRO & CDMO technology company that specializes in packaging recombinant adeno-associated virus (rAAV) vectors. Since its establishment in 2014, PackGene has been a leader in the AAV vector CRO service field, providing tens of thousands of custom batches of AAV samples to customers in over 20 countries. PackGene offers a one-stop CMC solution for the early development, pre-clinical development, clinical trials, and drug approval of rAAV vector drugs for cell and gene therapy (CGT) companies that is fast, cost-effective, high-quality, and scalable. Additionally, the company provides compliant services for the GMP-scale production of AAVs and plasmids for pharmaceutical companies, utilizing five technology platforms, including the π-Alpha 293 cell AAV high-yield platform and the π-Omega plasmid high-yield platform. PackGene's mission is to make gene therapy affordable and accelerate the launch of innovative gene drugs. The company aims to simplify the challenging aspects of gene therapy development and industrialization processes and provide stable, efficient, and economical rAAV Fast Services to accelerate gene and cell therapy development efforts from discovery phase to commercialization.
Rare diseases currently afflict 300 million people worldwide and 30 million people in the U.S. alone. However, 95% of these diseases lacked an FDA-approved treatment as of January 2023. One reason, industry leaders say, is cost. A 2019 study estimated that orphan drug...
SN Bioscience's pioneering nanoparticle anticancer drug, SNB-101, has sparked hope for patients battling various forms of cancer. Developed from the highly insoluble SN-38 into polymer nanoparticles, SNB-101 has exhibited significant improvements in efficacy and...
BioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC)
- Conducted in Collaboration with Columbia University, the CheMo4METPANC Phase 2 trial is the first large, multi-center, randomized study evaluating motixafortide with a PD-1 inhibitor and first-line PDAC chemotherapies compared to chemo alone - - Gulam Manji, MD,...
The success of mRNA vaccines against COVID-19 has unleashed a flood of interest in using the technology to create more vaccines and treatments for everything from rare diseases and infections to cancer. But before new mRNA therapeutics are put to use, they need to be...